Article Text

Download PDFPDF

P54 Screening for primary aldosteronism in hypertensive patients with systemic lupus erythematosus: are we doing it enough?
  1. Matthew Wong1,
  2. Alberta Y Hoi2,3,
  3. Joanna R Kent4,
  4. Eric F Morand2,3,
  5. Jun Yang1,5,6 and
  6. Fabien B Vincent2
  1. *Equal contributors
  2. 1Dept. of Medicine, Monash University, Clayton, Victoria, Australia
  3. 2Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
  4. 3Dept. of Rheumatology, Monash Health, Clayton, Victoria, Australia
  5. 4Dept. of Nephrology, Monash Health, Clayton, Victoria, Australia
  6. 5Dept. of Endocrinology, Monash Health, Clayton, Victoria, Australia
  7. 6Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia

Abstract

Objective Cardiovascular disease is one of the two leading causes of mortality in systemic lupus erythematosus (SLE). Hypertension, a traditional cardiovascular risk factor, is highly prevalent in SLE. Primary aldosteronism (PA), the most common endocrine cause of hypertension, remains under-screened and under-diagnosed, despite targeted treatment and surgical cure for PA being associated with a greater reduction in cardiovascular risk compared to blood pressure matched-essential hypertension. One study reported an association between PA and new onset of autoimmune diseases including SLE. However, whether PA contributes to hypertension in SLE has never been investigated. We aimed to determine the proportion of SLE patients with hypertension 1- meeting screening criteria for PA, 2- screened with an aldosterone-renin ratio (ARR), and 3- diagnosed with PA. We aimed to assess whether patients qualifying for PA screening had differences in SLE disease outcomes compared to those who did not.

Methods SLE patients attending the Monash Health lupus clinic between 2013–2022 were included in this retrospective study. Disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000) and organ damage (Systemic Lupus International Collaborative Clinics Damage Index) were assessed. Hypertension was defined as blood pressure ≥140 and/or ≥90 on 2+ clinical visits, or a documented diagnosis. Assessment for meeting PA screening criteria was conducted according to the Endocrine Society’s 2016 guidelines.

Results 322 patients were analysed (median age 41 years, 87% female; median disease duration and follow-up period: 6 years for both). Of those, 55% (178/322) had hypertension, and 8.7% (28/322) had drug-resistant hypertension. Of the hypertensive patients, 42.1% (75/178) were not recorded as such in medical records. 30% (95/322) met at least one criterion for PA screening; of those, 11% (10/95) were screened, including one abnormal result, and five suspicious results due to interfering medications. Patients qualifying for PA screening had higher renal disease activity and higher prevalence of cardiovascular and renal organ damage.

Conclusions Hypertension was highly prevalent, including 8.7% with resistant hypertension. Despite nearly a third qualifying for PA screening, only 11% were screened. Further research is needed to assess the prevalence of PA in SLE and its associations with disease outcomes.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.